or Try an Advanced Search...

    Technical Analysis for AIM - AIM ImmunoTech Inc.

    Grade Last Price % Change Price Change
    D 0.43 5.34% 0.02
    AIM closed up 5.34 percent on Friday, April 26, 2024, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical AIM trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 5.34%
    MACD Bearish Centerline Cross Bearish 5.34%
    Wide Bands Range Expansion 5.34%
    Lower Bollinger Band Touch Weakness 5.34%
    Oversold Stochastic Weakness 5.34%
    Older End-of-Day Signals for AIM ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 11 hours ago
    Possible Inside Day about 11 hours ago
    Up 3% about 15 hours ago
    Up 2% about 15 hours ago
    Up 1% about 15 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AIM Chart by TradingView
    Basic chart:

    Profile

    AIM ImmunoTech Inc. Description

    AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Disease Acid Infectious Diseases Health Care Melanoma Pancreatic Cancer Hepatitis B Carcinoma HIV Interferon Renal Cell Carcinoma Treatment Of Hepatitis Treatment Of Hepatitis B Chronic Fatigue Syndrome

    Is AIM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 19 AIM ImmunoTech files to sell 9.98M shares of common stock for holders
    Apr 15 AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
    Apr 10 AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
    Apr 2 AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript
    Apr 2 AIM ImmunoTech GAAP EPS of -$0.60, revenue of $0.2M
    Apr 2 AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Apr 2 Earnings Scheduled For April 2, 2024
    Apr 1 AIM ImmunoTech FY 2023 Earnings Preview
    Mar 26 AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
    Mar 25 AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
    See more AIM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.7487
    52 Week Low 0.3201
    Average Volume 243,620
    200-Day Moving Average 0.49
    50-Day Moving Average 0.43
    20-Day Moving Average 0.48
    10-Day Moving Average 0.45
    Average True Range 0.05
    RSI (14) 45.36
    ADX 26.74
    +DI 14.95
    -DI 24.69
    Chandelier Exit (Long, 3 ATRs) 0.46
    Chandelier Exit (Short, 3 ATRs) 0.53
    Upper Bollinger Bands 0.59
    Lower Bollinger Band 0.38
    Percent B (%b) 0.23
    BandWidth 42.27
    MACD Line 0.00
    MACD Signal Line 0.01
    MACD Histogram -0.0141
    Fundamentals Value
    Market Cap 20.91 Million
    Num Shares 48.8 Million
    EPS -0.43
    Price-to-Earnings (P/E) Ratio -1.00
    Price-to-Sales 100.75
    Price-to-Book 0.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.46
    Resistance 3 (R3) 0.45 0.44 0.45
    Resistance 2 (R2) 0.44 0.43 0.44 0.45
    Resistance 1 (R1) 0.43 0.43 0.44 0.44 0.45
    Pivot Point 0.42 0.42 0.42 0.42 0.42
    Support 1 (S1) 0.42 0.42 0.42 0.42 0.41
    Support 2 (S2) 0.40 0.41 0.40 0.41
    Support 3 (S3) 0.40 0.40 0.40
    Support 4 (S4) 0.40